FBN1 and Hyperglycemia: Romere et al. noticed that a single dose of recombinant asprosin injected subcutaneously in mice led to hyperglycemia and hyperinsulinemia; neutralization of asprosin by asprosin-specific antibodies resulted in ameliorated IR and dropped plasma glucose, insulin levels as well as body weight.